RxDoctor Payments Data

Richard Carano, MD

Endocrinology, Diabetes & Metabolism · Ames, IANPI 1518954502

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $199 of the $299 with a category attached, or 66.5%. Abbott accounts for 84.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $164 and has fallen 89.5% since, to $17 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in IA, where the typical reported total is $480.

$299in general payments, 2019–2025

Across 14 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$252
  • Amgen$19
  • Insulet Corporation$15
  • Lilly USA, LLC$12

What the payments were for

  • Food & beverage$19967%
  • Education$10033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott11$252
Amgen1$19
Insulet Corporation1$15
Lilly USA, LLC1$12

How this compares

$299 in reported general payments places this provider in the 35th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.

See all endocrinology, diabetes & metabolism providers in Iowa

Medicare billing

Part B allowed, 2024
$348,119
Medicare patients
780
Services billed
9,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide1,010$1,202,858
JardianceEmpagliflozin776$765,707
MounjaroTirzepatide231$287,599
TrulicityDulaglutide208$248,952
Tresiba Flextouch U-200Insulin Degludec209$217,433
Tresiba Flextouch U-100Insulin Degludec283$155,929
Humulin R U-500 KwikpenInsulin Regular, Human62$141,472
Fiasp FlextouchInsulin Aspart (Niacinamide)117$113,473
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/771$98,817
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog101$96,009
Novolog FlexpenInsulin Aspart326$86,772
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog159$80,165
FarxigaDapagliflozin Propanediol90$77,537
Lantus SolostarInsulin Glargine,hum.Rec.Anlog413$64,843
JanuviaSitagliptin Phosphate90$61,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$12$569,383604 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.

Other endocrinology, diabetes & metabolism in Ames

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →